# Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)

> **NCT06222034** · PHASE1 · RECRUITING · sponsor: **Alfasigma S.p.A.** · enrollment: 10 (estimated)

## Conditions studied

- Juvenile Idiopathic Arthritis

## Interventions

- **DRUG:** Filgotinib
- **DRUG:** Filgotinib

## Key facts

- **NCT ID:** NCT06222034
- **Lead sponsor:** Alfasigma S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-13
- **Primary completion:** 2026-03
- **Final completion:** 2026-08
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06222034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06222034, "Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06222034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*